Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients
Personalized genetic treatments using antisense oligonucleotides show early promise in treating children with rare SCN2A-related epilepsy.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Two severely affected patients with SCN2A mutations have received bespoke antisense oligonucleotides (ASOs) to target allele-specific faulty mRNA. This individualized gene therapy approach is being used to treat SCN2A-related developmental epileptic encephalopathy.
Coverage from Nature Medicine and Discover Magazine emphasizes that the treatment has shown impressive benefits alongside excellent safety and tolerability profiles. Contemporary Pediatrics describes the early results as promising for those with this rare mutation.
Future focus remains on the application of these personalized genetic treatments for patients with SCN2A-related conditions, as detailed in reports from Nature and Hackaday.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 18m ago.
Quick answers
What is being used to treat the SCN2A mutation?
Bespoke antisense oligonucleotides (ASOs) are being used as an individualized gene therapy.
Who has participated in this treatment so far?
Two severely affected children with the mutation have been treated.
What were the reported outcomes of the treatment?
The treatment showed impressive benefits and excellent safety and tolerability profiles.
Coverage (5)
- Impressive Benefits and an Excellent Safety and Tolerability Profiles in Two Severely Affected Patients With Mutations in a Vital Sodium Channel (SCN2A) Treated With Bespoke ASOs Reported in Nature Medicine Yahoo Finance Singapore · 16h ago
- Two Children With a Rare Epilepsy Mutation Show Improvement After Personalized Genetic Treatment Discover Magazine · 16h ago
- Individualized gene therapy shows early promise for SCN2A-related epileptic encephalopathy Contemporary Pediatrics · 16h ago
- Individualized antisense oligonucleotides for SCN2A- related developmental epileptic encephalopathy Nature · 16h ago
- Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients Hackaday · 16h ago
Topics
Related trends
Boston Children’s and the Broad Institute partner on new center for rare genetic diseases
Three major institutions have launched the Center for Therapeutic Genetics to develop medicines for rare and ultra-rare genetic diseases.
MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
MeiraGTx has secured significant new funding from Oberland Capital to advance two gene therapies toward commercialization.
FDA’s top gene therapy regulator is leaving his role
The FDA's top gene therapy regulator is stepping down, amid a significant setback for a kidney disease drug.
Louisiana Notches a Sickle Cell First
A Louisiana man is the first in the state to be functionally cured of sickle cell disease.
Exclusive | FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
The FDA is reversing its rejection of Regenxbio's gene therapy for Hunter syndrome, marking the third such reversal for rare-disease drugs.
Scientists test first-ever therapy to make human cells young again
Human trials have officially commenced for the first-ever gene therapy designed to rejuvenate human cells and reverse aging.